Alar Pharmaceuticals
Taipei, Taiwan· Est.
Taiwanese biotech delivering long‑acting injectables for CNS and chronic pain via the In‑Relar platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $50M
AI Company Overview
Taiwanese biotech delivering long‑acting injectables for CNS and chronic pain via the In‑Relar platform.
CNS DisordersChronic PainOsteoarthritis
Technology Platform
In‑Relar is a proprietary long‑acting release platform that delivers low‑viscosity, small‑volume injectable solutions with sustained drug release over weeks to months.
Opportunities
Alar can leverage its In‑Relar platform to rapidly expand into multiple CNS and chronic pain indications, and the 505(b)(2) pathway may accelerate FDA approval and market entry.
Risk Factors
Key risks include regulatory hurdles for novel long‑acting injectables, clinical trial outcomes, and competition from larger firms with established LAR pipelines.
Competitive Landscape
Competitors such as Alkermes, Janssen, and Amgen are developing long‑acting injectables for CNS disorders; Alar differentiates itself through its low‑viscosity, small‑volume formulation and focus on the 505(b)(2) pathway.